FRUZAQLA® (fruquintinib) patient profiles*
Explore 2 potential mCRC patient types and learn how they may benefit from treatment with FRUZAQLA
Barbara*
58-year-old patient with mCRC and liver metastasis†
Diagnosis
- Diagnosed with unresectable left-sided mCRC 23 months ago
- Presented with metastasis in multiple sites, including liver
- Molecular profiling of primary tumor:
- Microsatellite stable; MMR proficient with no actionable mutation
Treatment History
- Initiated treatment with FOLFOX + bevacizumab
- CT scans at 2 months and 4 months showed decreased size of liver lesions
- CT scan at 14 months revealed disease progression
- Greater degree of metastasis, with an increase in liver lesion size
- Progressive disease in the lymph nodes
- Subsequent treatment with FOLFIRI
- Disease progression after 6 months on her most recent treatment, with evidence of new lesions and pulmonary metastasis
Next steps
Considerations
- ECOG PS 1
- ALT: 22UI/L; AST:25 IU/L (normal levels)
- Would like to pursue more treatment
Barbara needs a treatment that
- Extends survival while delaying or maintaining time to deterioration of symptoms
- Has demonstrated prolongation of survival in patients with liver metastasis after 2 types of chemotherapy + bevacizumab
- Satisfies her desire to make fewer visits to the hospital for treatment administration
- Minimizes the impact of her treatment on her activities of daily life
Mark*
64-year-old patient with mCRC presenting with myelosuppression
Diagnosis
- Diagnosed with high-risk Stage III adenocarcinoma of the colon
- Molecular profiling of primary tumor
- Microsatellite stable; MMR-proficient with no actionable mutation
Treatment history
- Surgery with 12 cycles of subsequent FOLFOX adjuvant therapy
- CT scan 7 months after completion of adjuvant therapy revealed recurrence in the liver and progressive disease in lymph nodes
- Initiated treatment with FOLFIRI + bevacizumab with progression after 4 months
- Blood test results demonstrated:
- Neutropenia (ANC 1200/mm3) that persisted for >30 days, eventually resolved with G-CSF
- Thrombocytopenia (platelet count 110,000/mm3) that persisted for >30 days
Next steps
Considerations
- ECOG PS 0
- Need for disease control given the extent of distant metastasis
- Would prefer minimal interference with current lifestyle
Mark needs a treatment that
- Extends survival while delaying or maintaining time to deterioration of symptoms
- Has demonstrated tolerability, particularly with a low risk of inducing myelosuppression
- Offers convenient dosing that doesn’t require infusion center visits for treatment
- Minimizes the impact of his treatment on his activities of daily life
Convenient, Once-Daily Oral Dosing
Discover simple, once-daily dosing with FRUZAQLA.
FRESCO-2 Efficacy Results
Learn about the efficacy results from FRESCO-2, a global, double-blind, placebo-controlled study with a heterogenous patient population.
FRESCO-2 Safety Profile
Explore the safety profile of FRUZAQLA from the FRESCO-2 clinical trial.
ALT=alanine aminotransferase; ANC=absolute neutrophil count; CT=computed tomography; ECOG PS=Eastern Cooperative Oncology Group performance status;
FOLFIRI=leucovorin calcium (folinic acid), fluorouracil, and irinotecan; FOLFOX=leucovorin calcium (folinic acid), fluorouracil, and oxaliplatin; G-CSF=granulocyte-colony stimulating factor; MMR=mismatch repair; ULN=upper limit of normal.
*Hypothetical patient. Individual patient results may vary.
†FRUZAQLA should not be used in patients with severe hepatic impairment (total bilirubin >3 times ULN and any AST). Please see full Prescribing Information for more information.1